Auricchio A, Gao G-P, Yu Q C, Raper S, Rivera V M, Clackson T, Wilson J M
Institute for Human Gene Therapy, The Wistar Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Gene Ther. 2002 Jul;9(14):963-71. doi: 10.1038/sj.gt.3301746.
To test whether hepatocytes engineered in vivo can serve as surrogate beta cells by similarly secreting mature insulin in a glucose-sensitive manner, we prepared adenoviral vectors encoding wild-type proinsulin (hIns-wt), a modified proinsulin cleavable by the ubiquitously expressed protease furin (hIns-M3), or each of the two beta cell specific pro-insulin convertases PC2 and PC3. Following a detailed in vitro characterization of the proteins produced by our vectors, we infected the liver and, for comparison, the muscle of a chemically induced murine model of type I diabetes. Insulin expression from the transduced tissues was extensively characterized and showed to be constitutive rather than regulated. To obtain regulated expression, we placed expression of hIns-M3 under the control of the dimerizer-inducible transcription system. Hormone secretion from mouse liver was negligible in the absence of the dimerizer drug rapamycin, was inducible in a dose-dependent manner upon its administration, and reversible following drug withdrawal. These data confirm liver as a promising target for in vivo expression of processed insulin. While suggesting that hepatocytes cannot provide authentic glucose-responsive regulation, these results demonstrate that pharmacological regulation is a promising alternative route to the controlled delivery of insulin following hepatic gene transfer.
为了测试体内工程化的肝细胞是否能够通过以葡萄糖敏感的方式类似地分泌成熟胰岛素来充当替代β细胞,我们制备了编码野生型胰岛素原(hIns-wt)、可被普遍表达的蛋白酶弗林蛋白酶切割的修饰胰岛素原(hIns-M3)或两种β细胞特异性胰岛素原转化酶PC2和PC3的腺病毒载体。在对我们的载体产生的蛋白质进行详细的体外表征之后,我们感染了化学诱导的I型糖尿病小鼠模型的肝脏,并作为对照感染了其肌肉。对转导组织中的胰岛素表达进行了广泛表征,结果显示其为组成型而非受调控型。为了获得受调控的表达,我们将hIns-M3的表达置于二聚体诱导转录系统的控制之下。在没有二聚体药物雷帕霉素的情况下,小鼠肝脏的激素分泌可以忽略不计,给药后其分泌呈剂量依赖性诱导,停药后可逆转。这些数据证实肝脏是体内表达加工后胰岛素的一个有前景的靶点。虽然提示肝细胞不能提供真正的葡萄糖反应性调节,但这些结果表明,药理学调节是肝基因转移后胰岛素可控递送的一个有前景的替代途径。